GlassScriptPhysician profile
Sondra Ware
NPI 1386181444
$2,338.73
in general payments reported to CMS, 2019-2025
31 companies · $627 in 2025
The $627 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $108 · 2022: $474 · 2023: $569 · 2024: $560 · 2025: $627.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,757.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,756.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $291.65 | 2021-2025 | Sublocade |
| Abbvie INC. | $195.62 | 2021-2024 | |
| Alkermes, INC. | $191.15 | 2021-2023 | Aristada, Vivitrol, Lybalvi |
| Novo Nordisk INC | $189.45 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Otsuka America Pharmaceutical, INC. | $171.50 | 2023-2025 | Rexulti, Nuedexta |
| Bayer Healthcare Pharmaceuticals INC. | $154.69 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $152.65 | 2022-2025 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $127.98 | 2022-2024 | Evusheld |
| Astellas Pharma US INC | $127.07 | 2022-2025 | Veozah, Myrbetriq |
| Horizon Therapeutics Plc | $124.56 | 2023 | Krystexxa |
| Idorsia Pharmaceuticals US INC | $86.65 | 2022-2023 | Quviviq |
| Exact Sciences Corporation | $76.86 | 2023-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $54.97 | 2022-2023 | Xifaxan |
| Viiv Healthcare Company | $39.47 | 2024 | Apretude |
| Amgen INC. | $34.94 | 2024 | Krystexxa |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fidia Pharma USA INC. | $34.76 | 2025 | Hymovis, Triluron |
| Eisai INC. | $33.76 | 2021 | |
| Lilly USA, LLC | $33.43 | 2024-2025 | Mounjaro, Zepbound |
| Hologic Sales and Service, LLC | $26.24 | 2025 | Thinprep 2000 Processor, Aptima |
| Biohaven Pharmaceutical Holding Company LTD. | $19.70 | 2022 | |
| Krystal Biotech INC | $18.96 | 2025 | Vyjuvek |
| Dexcom, INC. | $18.83 | 2023 | Dexcom G6 Transmitter |
| Braeburn INC. | $18.11 | 2024 | Brixadi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.78 | 2022 | |
| Neurocrine Biosciences, INC. | $16.87 | 2024 | Ingrezza |
| Pfizer INC. | $14.74 | 2023 | |
| Aimmune Therapeutics, INC. | $14.37 | 2024 | |
| Insulet Corporation | $14.12 | 2025 | Omnipod |
| Sumitomo Pharma America, INC. | $14.11 | 2024 | Gemtesa |
| Scilex Pharmaceuticals INC. | $12.27 | 2022 | |
| Uswm, LLC | $11.47 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sondra Ware listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.